Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

PURPOSE: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal antibody against IGF-IR. Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. EXPERIMENTA...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Beltran, Pedro J., Calzone, Frank J., Mitchell, Petia, Chung, Young-Ah, Cajulis, Elaina, Moody, Gordon, Belmontes, Brian, Li, Chi-Ming, Vonderfecht, Steven, Velculescu, Victor E., Yang, Guorong, Qi, Jingwei, Slamon, Dennis J., Konecny, Gottfried E.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4138720/
https://ncbi.nlm.nih.gov/pubmed/24727326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3448
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares